van Joost T, Blog F B, Westerhof W, Jansen F C, Starink T M, den Boer M S, Kuneman J J, Harvey S G, Gibson J R
Department of Dermatology and Venereology, Erasmus University Rotterdam, The Netherlands.
J Int Med Res. 1989;17 Suppl 2:14B-17B.
Patients (n = 56) with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of acrivastine at two doses (8 and 4 mg) versus 60 mg terfenadine and placebo administered three times daily. All three active preparations were found to be effective, and significantly better than placebo, in controlling the signs and symptoms of urticaria. No significant differences were found between the active preparations, although in some cases efficacy trends favoured 8 mg acrivastine and terfenadine over 4 mg acrivastine. No significant differences were noted between the active treatments and placebo with regard to reports of drowsiness.
在一项完全随机、双盲、交叉研究中，对56例诊断为慢性特发性荨麻疹的患者进行了评估，以研究两种剂量（8毫克和4毫克）的阿伐斯汀与每日三次服用60毫克特非那定及安慰剂相比的疗效。结果发现，所有三种活性制剂在控制荨麻疹的体征和症状方面均有效，且显著优于安慰剂。尽管在某些情况下，疗效趋势显示8毫克阿伐斯汀和特非那定优于4毫克阿伐斯汀，但活性制剂之间未发现显著差异。在嗜睡报告方面，活性治疗与安慰剂之间未发现显著差异。
